CSB 2.009 History
History:
Cr.
Register, April, 1976, No. 244, eff. 5-1-76.
CSB 2.009 Note
CSB 2.10 Addition of propiram to schedule I. Paragraph (wn) of sub. (2), s.
161.14, Stats., schedule I is hereby created to read:
CSB 2.009 Note
(wn) Propiram
CSB 2.009 History
History:
Cr.
Register, August, 1976, No. 248, eff. 9-1-76.
CSB 2.009 Note
CSB 2.11 Renumbering and addition to schedule IV of diethylpropion and phentermine. Paragraph (a) of sub. (2m), s. 161.20, Stats., schedule IV is hereby renumbered to read:
CSB 2.009 Note
(b) Fenfluramine
CSB 2.009 Note
Paragraph (a) of sub. (2m), s. 161.20, Stats., schedule IV is hereby created to read: CSB 2.009 Note
(a) Diethylpropion
CSB 2.009 Note
Paragraph (b) of sub. (2m), s. 161.20, Stats., schedule IV is hereby renumbered to read:
CSB 2.009 Note
(c) Pemoline
CSB 2.009 NoteParagraph (d) of sub. (2m), s.
161.20, Stats., schedule IV is hereby created to read:
CSB 2.009 Note
(d) Phentermine
CSB 2.009 History
History:
Cr.
Register, August, 1976, No. 248, eff. 9-1-76.
CSB 2.009 Note
CSB 2.13 Addition of dextropropoxyphene to schedule IV. Subsection (4), s.
161.20, Stats., schedule IV is hereby created to read:
CSB 2.009 Note
(4) Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts:
CSB 2.009 Note
(a) Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane)
CSB 2.009 History
History:
Cr.
Register, November, 1977, No. 263, eff. 12-1-77.
CSB 2.009 Note
CSB 2.14 Addition of prazepam to schedule IV. Paragraph (km), sub. (2), s.
161.20, Stats., schedule IV is hereby created to read:
CSB 2.009 Note
(km) Prazepam
CSB 2.009 History
History:
Cr.
Register, November, 1977, No. 263, eff. 12-1-77.
CSB 2.009 Note
CSB 2.15 Addition of parahexyl to schedule I; removal of loperamide from schedule V; addition of triazolam to schedule IV. (1) Paragraph (mn) of sub. (4), s.
161.14, Stats., is created to read:
CSB 2.009 Note
(mn) Parahexyl
CSB 2.009 Note
(2) Paragraph (a) of sub. (3), s. 161.22, Stats., is repealed.
CSB 2.009 Note
(3) Paragraph (nm) of sub. (2), s.
161.20, Stats., is created to read:
CSB 2.009 Note
(nm) Triazolam
CSB 2.009 History
History:
Cr.
Register, October, 1984, No. 346, eff. 11-1-84.
CSB 2.009 Note
CSB 2.16 Transfer of sufentanil from schedule I to schedule II. (1) Section 161.14 (2) (xg), Stats., is repealed.
CSB 2.009 Note
(2) Section
161.16 (3) (y), Stats., is created to read:
CSB 2.009 Note
(y) Sufentanil
CSB 2.009 History
History:
Cr.
Register, October, 1984, No. 346, eff. 11-1-84.
CSB 2.009 Note
CSB 2.17 Addition of buprenorphine to schedule V; transfer of methaqualone from schedule II to schedule I; transfer of dronabinol from schedule I to schedule II. (2) Paragraph (b) of s.
161.14 (5), Stats., is adopted to read:
CSB 2.009 Note
(b) Methaqualone
CSB 2.009 Note
(3) Subsection (7) (am) of s. 161.16, Stats., is repealed.
CSB 2.009 Note
(4) Subsection
(10) (a) of s.
161.16, Stats., is created to read:
CSB 2.009 Note
(10) Hallucinogenic substances. (a) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. food and drug administration approved drug product. (Other names for dronabinol are (6a R - trans) - 6a, 7, 8, 10a - tetrahydro - 6, 6, 9 - trimethyl - 3 -pentyl-6H-dibenzo (b, d) pyran - 1 - ol, or (-) - delta - 9 - (trans) - tetrahydrocannabinol.)
CSB 2.009 History
History:
Cr.
Register, August, 1986, No. 368, eff. 9-1-86;
CR 03-056: r. (1)
Register January 2004 No. 577, eff. 2-1-04.
CSB 2.009 Note
CSB 2.18 Addition of 3,4-methylenedioxymethamphetamine to schedule I. Paragraph (am) of s.
161.14 (4), Stats., is created to read:
CSB 2.009 Note
(am) 3, 4-methylenedioxymethamphetamine, commonly known as“MDMA";
CSB 2.009 History
History:
Cr.
Register, September, 1987, No. 381, eff. 10-1-87.
CSB 2.009 Note
CSB 2.19 Additions, deletions and transfers to statutory schedules. (1) Paragraph (b) of s.
161.20 (4), Stats., is created to read:
CSB 2.009 Note
(b) Not more than 25 milligrams per dosage unit of pentazocine with one or more active, non-narcotic ingredients in recognized therapeutic amounts.
CSB 2.009 Note
(2) Paragraph (b) of s. 161.18 (4), Stats., is repealed.
CSB 2.009 Note
(3) Paragraph (km) of s. 161.20 (2), Stats., is renumbered to read:
CSB 2.009 Note
(mg) Prazepam;
CSB 2.009 Note
(4) Paragraph (hg) of s.
161.20 (2), Stats., is created to read:
CSB 2.009 Note
(hg) Midazolam;
CSB 2.009 Note
(5) Paragraph (mm) of s.
161.20 (2), Stats., is created to read:
CSB 2.009 Note
(mm) Quazepam;
CSB 2.009 Note
(6) Paragraph (km) of s.
161.18 (3), Stats., is created to read:
CSB 2.009 Note
(km) Tiletamine and Zolazepam or any salt thereof;
CSB 2.009 Note
(7) Paragraph (a) of s. 161.16 (3), Stats., is renumbered to read:
CSB 2.009 Note
(am) Alphaprodine;
CSB 2.009 Note
(8) Paragraph (a) of s.
161.16 (3), Stats., is created to read:
CSB 2.009 Note
(a) Alfentanil;
CSB 2.009 Note
(9) Paragraph (rg) of s.
161.14 (2), Stats., is created to read:
CSB 2.009 Note
(rg) MPPP 1-methyl-4-phenyl-4-propionoxypiperidine);
CSB 2.009 Note
(10) Paragraph (vg) of s.
161.14 (2), Stats., is created to read:
CSB 2.009 Note
(vg) (PEPAP) 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine;
CSB 2.009 Note
(11) Paragraph (b) of s.
161.16 (10), Stats., is created to read:
CSB 2.009 Note
(b) Nabilone (another name for nabilone: (+)-trans-3- (1,1-dimethylheptyl)-6, 6a, 7, 8, 10, 10a-hexahydro-1- hydroxy-6, 6-dimethyl-9H-dibenzo [b,d] pyran-9-one).
CSB 2.009 Note
(12) Subsection
(2) of s.
161.14, Stats., is amended to read:
CSB 2.009 Note
(2) Opiates. Unless specifically excepted under federal regulations or unless listed in another schedule, any of the following opiates, or their isomers, esters, ethers, salts, salts of isomers, esters of ethers, if isomers, esters, ethers, salts or salts of isomers exist within the specified chemical designation (for purposes of par. (tg) only, the term isomer includes the optical and geometric isomers):
CSB 2.009 Note
(13) Paragraph (a) of s. 161.14 (2), Stats., is renumbered to read:
CSB 2.009 Note
(ag) Acetylmethadol;
CSB 2.009 Note
(14) Paragraph (a) of s.
161.14 (2), Stats., is created to read:
CSB 2.009 Note
(a) Acetyl-alpha-methylfentanyl (N-(1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
CSB 2.009 Note
(15) Paragraph (cg) of s.
161.14 (2), Stats., is created to read:
CSB 2.009 Note
(cg) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
CSB 2.009 Note
(16) Paragraph (dg) of s.
161.14 (2), Stats., is created to read:
CSB 2.009 Note
(dg) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl) -4-piperidinyl]-N-phenylpropanamide);
CSB 2.009 Note
(17) Paragraph (rj) of s.
161.14 (2), Stats., is created to read:
CSB 2.009 Note
(rj) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl) ethyl-4-piperidinyl]-N-phenylpropanamide);
CSB 2.009 Note
(18) Paragraph (tg) of s.
161.14 (2), Stats., is created to read:
CSB 2.009 Note
(tg) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1- (2-phenethyl)-4-piperidinyl]propanamide);
CSB 2.009 Note
(19) Paragraph (xm) of s.
161.14 (2), Stats., is created to read:
CSB 2.009 Note
(xm) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]propanamide);
CSB 2.009 History
History:
Cr.
Register, February, 1988, No. 386, eff. 3-1-88.
CSB 2.009 Note
CSB 2.20 Addition of beta-hydroxy-3-methylfentanyl to schedule I. Paragraph (er) of s.
161.14 (2), Stats., is created to read:
CSB 2.009 Note
(er) Beta-hydroxy-3-methylfentanyl.
CSB 2.009 History
History:
Cr.
Register, July, 1989, No. 403, eff. 8-1-89.
CSB 2.009 Note
CSB 2.21 Additions, deletions, corrections, transfers, and amendments to drug schedules. (1) Subsection
(1) of s.
161.14, Stats., is amended to read:
CSB 2.009 Note
(1) Included substances. Unless specifically excepted by state or federal law or regulation or more specifically included in another schedule, the following controlled substances are listed in schedule I.
CSB 2.009 Note
(2) Paragraph (a) of s.
161.14 (2), Stats., is amended to read:
CSB 2.009 Note
(a) Acetyl-alpha-methylfentany (N-[1-(1-methyl-2-phenylethyl)-4-piperidinyl]-N-phenylacetamide);
CSB 2.009 Note
(3) Paragraph (er) of s.
161.14 (2), Stats., is amended to read:
CSB 2.009 Note
(er) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2- phenylethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);
CSB 2.009 Note
(4) Paragraph (rg) of s.
161.14 (2), Stats., is amended to read:
CSB 2.009 Note
(rg) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
